Bergenbio ASA

BerGenBio ASA appoints Olav Hellebø as CEO, leveraging his 30 years of experience in pharmaceuticals and biotechnology, including roles at ReNeuron Group PLC and Clavis Pharma ASA. Hellebø aims to advance BerGenBio's candidate drug, bemcentinib, for non-squamous non-small cell lung cancer with STK11 mutations.

BerGenBio ASA (FRA:7BG0) identified a significant unmet medical need in STK 11 mutated patients, received FDA fast-track designation, and has a strong safety database. However, faced administrative delays, discontinued Sylvest program, and CEO Martin Olin is leaving. Interim BTBC 16 study data expected early 2025, final phase two data as late as 2026.

BerGenBio ASA (FRA:7BG0) reports $40M revenue, $175M cash position, and FDA fast-track designation for STK 11 mutated patients. CEO Martin Olin's departure planned for smooth transition. Interim BTBC 16 study data expected early 2025, final phase two data by 2026. Sylvester program discontinued due to lack of partnerships. Limited news flow between quarterly updates maintained for data-driven transparency.